A systematic review and meta-analysis of 20 studies representing experience in 68,680 patients shows that use of omega-3 fatty acid supplementation does not improve cardiovascular risk factors. Published in The Journal of the American Medical Association, the report examined evidence from randomized clinical trials (RCTs) in MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials from as early as 1989 through August 2012.
A systematic review and meta-analysis of 20 studies representing experience in 68,680 patients shows that use of omega-3 fatty acid supplementation does not improve cardiovascular risk factors. Published in The Journal of the American Medical Association, the report examined evidence from randomized clinical trials (RCTs) in MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials from as early as 1989 through August 2012.
The RCTs included omega-3 administration and diet or placebo for primary or secondary cardiovascular disease (CVD). Studies with treatment duration less than 1 year were excluded to ensure sufficient time to prove efficacy of treatment in CVD prevention. The researchers also evaluated the methodological quality of the trials and assessed the risk of bias, using the Cochrane collaboration tool.
Most of the study participants were of European ancestry (15 studies; 49,314 participants) but the largest trial included 18,645 Japanese participants. In all but two trials, omega-3 supplements were used, at a mean dosage of 1.51 g/day; mean treatment duration was 2 years.
When all supplement studies were considered, no statistically significant association was observed for all-cause mortality (relative risk [RR], 0.96; 95% CI, 0.91 to 1.02; risk reduction [RD] -0.004, 95% CI, -0.01 0.02), cardiac death (RR, 0.91; 95% CI, 0.85 to 0.98; RD -0.01; 95% CI, -0.02 to 0.00), sudden death (RR, 0.87; 95% CI, 0.75 to 1.01; RD, -0.003, 95% CI, -0.012 to 0.006), myocardial infarction (RR, 0.89; 95% CI, 0.76 to 1.04; RD, -0.002; 95% CI, -0.007 to 0.002), or stroke (RR, 1.05; 95% CI, 0.93 to 1.18; RD, 0.001; 95% CI, -0.002 to 0.004). Neither study-specific nor population-specific characteristics were associated with the observed effect of omega-3.
Read other articles in this issue of Special Delivery.
Adverse maternal outcomes after uterine conservation in placenta accreta spectrum
May 9th 2024A review of 5 studies reveals a significant 1 in 4 incidence of adverse maternal outcomes following uterine conservation in patients with placenta accreta spectrum, underlining the importance of expert multidisciplinary care.
Read More
Barriers in seeking pelvic floor disorder treatment among ethnic minorities
May 8th 2024A recent shed light on how ethnic minority groups perceive pelvic floor disorders, highlighting barriers to treatment seeking and the importance of raising awareness about available treatment options.
Read More
Variations found in testosterone therapy for women with HSDD
May 7th 2024Dive into the intricate landscape of testosterone therapy prescriptions among women with hypoactive sexual desire disorder, revealing diverse patterns in duration, administration routes, and estrogen co-administration.
Read More